Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2009 | 06-2009 | 03-2009 | 12-2008 | 09-2008 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 98,087 | 147,870 | 227,268 | 194,791 | 199,737 |
| Marketable Securities | 119,883 | 119,368 | 180,786 | 238,596 | 223,379 |
| Receivables | 5,022 | 5,857 | 5,831 | 4,188 | 24,140 |
| Income taxes - deferred | N/A | N/A | N/A | 875 | N/A |
| TOTAL | $228,165 | $278,422 | $419,339 | $443,124 | $451,779 |
| Non-Current Assets | |||||
| PPE Net | 18,152 | 18,483 | 19,321 | 19,194 | 19,577 |
| Investments And Advances | 243,374 | 215,434 | 106,360 | 83,904 | 104,746 |
| Intangibles | 665 | 708 | 751 | 795 | 838 |
| Other Non-Current Assets | 5,312 | 5,606 | 8,758 | 7,659 | 3,241 |
| TOTAL | $267,503 | $240,231 | $135,190 | $111,552 | $128,402 |
| Total Assets | $495,668 | $518,653 | $554,529 | $554,676 | $580,181 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 8,426 | 6,463 | 8,729 | 2,588 | 3,342 |
| Accrued Expenses | 8,381 | 9,908 | 10,389 | 9,328 | 9,859 |
| TOTAL | $101,121 | $102,331 | $104,251 | $99,452 | $102,024 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | N/A | N/A | N/A | 719 |
| Deferred Revenues | 83,257 | 84,131 | 84,100 | 81,425 | 81,609 |
| Other Non-Current Liabilities | 207 | 220 | 233 | 246 | 318 |
| TOTAL | $212,526 | $231,840 | $251,534 | $253,099 | $273,600 |
| Total Liabilities | $313,647 | $334,171 | $355,785 | $352,551 | $375,624 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 41,815 | 41,728 | 41,502 | 41,425 | 41,408 |
| Common Shares | 418 | 417 | 414 | 414 | 414 |
| Retained earnings | -292,041 | -282,833 | -260,131 | -252,242 | -242,850 |
| Other shareholders' equity | 1,889 | 1,621 | 623 | 1,186 | -1,099 |
| TOTAL | $182,021 | $184,482 | $198,744 | $202,125 | $204,557 |
| Total Liabilities And Equity | $495,668 | $518,653 | $554,529 | $554,676 | $580,181 |